Vlachostergios, Panagiotis J <br/><br/>
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.  [electronic resource] 

 -  Investigational new drugs  Oct 2013 
 - 1169-81 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-013-9968-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--administration & dosage<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Cell Line, Tumor<br/>Dacarbazine--administration & dosage<br/>Drug Resistance, Neoplasm--drug effects<br/>Humans<br/>Hypoxia-Inducible Factor 1, alpha Subunit--metabolism<br/>Mitogen-Activated Protein Kinases--metabolism<br/>NF-kappa B--metabolism<br/>O(6)-Methylguanine-DNA Methyltransferase--antagonists & inhibitors<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Pyrazines--administration & dosage<br/>STAT3 Transcription Factor--metabolism<br/>Temozolomide<br/>Tumor Suppressor Protein p53--metabolism